Stocktoria
Mereo BioPharma Group plc MREO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2016-06-09
Chart by TradingView
3/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Financials | ||||
| Revenue | $500,000 | $0 | $10.0M | $0 |
| Operating income | -$40.1M | -$47.4M | -$28.4M | -$54.4M |
| Net income | -$41.9M | -$43.3M | -$29.5M | -$42.2M |
| Operating cash flow | -$31.0M | -$32.8M | -$21.1M | -$48.8M |
| Free cash flow | -$31.0M | -$32.8M | -$21.1M | -$48.8M |
| Total assets | $45.9M | $76.4M | $66.5M | $77.4M |
| Total liabilities | $5.0M | $15.4M | $16.0M | $26.0M |
| Shareholders' equity | $40.9M | $61.0M | $50.5M | $51.4M |
| Ratios | ||||
| Operating margin | -8021.4% | — | -284.2% | — |
| Net margin | -8375.6% | — | -294.7% | — |
| FCF margin | -6198.2% | — | -211.3% | — |
| Return on assets | -91.2% | -56.6% | -44.3% | -54.5% |
| Return on equity | -102.4% | -70.9% | -58.3% | -82.1% |
| Current ratio | 10.46 | 5.40 | 6.72 | 3.09 |
| Revenue growth | — | -100.0% | — | — |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 48,400 | $15,972 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001719714 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.